News Archive

Read Article

HNCIG-ENDORSED RECOMMENDATIONS FOR POST-OP RT IN HNSCC IN PRESENCE OF FLAPS PUBLISHED BY GORTEC

Read Article

HNCIG CONSENSUS ON ENDPOINT DEFINITIONS IN RECURRENT AND METASTATIC HNSCC TRIALS PUBLISHED IN LANCET ONCOLOGY

Read Article

HNCIG CONSENSUS GUIDELINES FOR DIAGNOSING PATHOLOGIC EXTRANODAL EXTENSION PUBLISHED IN LANCET ONCOLOGY

Read Article

HNCIG CONSENSUS RECOMMENDATIONS FOR EXTRANODAL EXTENSION ON IMAGING IN HNSCC PUBLISHED IN LANCET ONCOLOGY

Read Article

HNCIG CONDUCTS MULTINATIONAL STUDY ON P16 AND HPV DISCORDANCE

This multicentre individual patient data analysis aimed to identify the extent of discordance and its prognostic implications. Read more

Read Article

TPEXTREME RANDOMIZED TRIAL PUBLISHED IN LANCET

Taxane-based TPEx regimen appears to be a new option in first line recurrent/metastatic HNSCC, with a shorter time on therapy and lower toxicity than the reference EXTREME regimen. This can provide an alternative to SOC with EXTREME regimen, especially for those who may not be good candidates for up-front pembrolizumab. Read more

Read Article